Drug intelligence / Profile preview

cyclosporine

Development stage
Approved
Lead developer
Novartis
Modality
Peptides, Small Molecules
Administration
Oral, Intravenous, Ophthalmic (eye Drops)
01

Overview

Cyclosporine is a cyclic undecapeptide immunosuppressant derived from the fungus Tolypocladium inflatum. It acts as a calcineurin inhibitor and is primarily used to prevent organ rejection in kidney, liver, and heart transplants. Cyclosporine is also indicated for severe active rheumatoid arthritis (when other treatments fail), severe plaque psoriasis (unresponsive to other systemic therapies), nephrotic syndrome due to glomerular diseases (including steroid-dependent or resistant cases), Crohn's disease, eczema, and as ophthalmic drops for keratoconjunctivitis sicca (dry eyes). Its mechanism involves binding to cyclophilin in T cells to form a complex that inhibits calcineurin phosphatase activity. This blocks dephosphorylation of nuclear factor of activated T cells (NF-AT), reducing transcription of cytokines such as IL-2 required for T cell activation and proliferation[1][3][6]. Cyclosporine has significantly improved outcomes in transplantation medicine by specifically suppressing lymphocyte function.

Brand names
NeoralSandIMMUNEGengrafApo-cycloSPORINERestasis
Other names
环孢素ciclosporin
02

Targets

PPIA (Peptidyl-prolyl cis-trans isomerase A)PPP3CA (Protein phosphatase 3 catalytic subunit alpha)

Beyond the preview

Go deeper on cyclosporine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclosporine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call